Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00699491

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Phase I/II Trial of IMC-A12 in Combination With Temsirolimus in Patients With Metastatic Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Male Breast Carcinoma Recurrent Breast Carcinoma Stage IV Breast Cancer AJCC v6 and v7

Interventions Cixutumumab Laboratory Biomarker Analysis Pharmacological Study Temsirolimus

Updated 10 times since 2017 Last updated: May 15, 2018 Started: Oct 31, 2008 Primary completion: Sep 9, 2013 Completion: Feb 14, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00699491, this PHASE1/PHASE2 trial focuses on Male Breast Carcinoma and Recurrent Breast Carcinoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 10 times since 2008, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2

▶ Show 5 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2
Jul 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adrian, United States , Ann Arbor, United States , Asheboro, United States , Aurora, United States , Bismarck, United States , Bloomington, United States , Boise, United States , Boulder, United States , Bowling Green, United States , Camden, United States and 113 more locations